Eleven of the leading US biosimilar developers have collaborated to form the Biosimilars Forum, a nonprofit organization formed to expand patient access to biosimilars.
On May 5, 2015 some of the leading biosimilar developers in the United States announced the launch of the Biosimilars Forum. The forum was developed by 11 companies with the most significant biosimilars development portfolios: Actavis, Amgen, Boehringer Ingelheim, Coherus BioSciences, EMD Serono, Hospira, Merck, Pfizer, Samsung, Sandoz, and Teva. “The Forum will provide evidence-based information to educate and advocate for public policies and practices that encourage access, awareness, and adoption of biosimilars,” according to a press release.
The officials who will lead the forum were announced in the press release and include:
The forum will submit a public statement on May 7, 2015 to the Centers for Medicare and Medicaid Services Healthcare Common Procedure Coding System to address the need for appropriate coding for biosimilars.
Source: Biosimilars Forum
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.